The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for ocriplasmin (Jetrea, Thrombogenics, NV) for the treatment of adults with ...

JETREA (ocriplasmin) 2.5mg/mL intravitreal injection by ThromboGenics The FDA has approved Jetrea (ocriplasmin; ThromboGeneics) for the treatment of symptomatic vitreomacular adhesion (VMA), a ...

ThromboGenics NV has announced that the European Commission has approved JETREA® (ocriplasmin) in the European Union. JETREA® is approved for the treatment of vitreomacular traction (VMT), including ...

The European Commission has approved the intravitreal eye injection Jetrea, produced by Novartis (NVS 0.99%) eye care subsidiary Alcon, for treating vitreomacular traction in the European Union. The ...

NICE today has issued final draft guidance that recommends ocriplasmin (Jetrea, manufactured by ThromboGenics) as a treatment option for some adults with vitreomacular traction. Ocriplasmin has been ...

JETREA is the first pharmacological treatment indicated for use in patients diagnosed with VMT, also when associated with macular hole of diameter less than or equal to 400 microns. It was approved ...

BRUSSELS (Reuters) – Belgian biotechnology company ThromboGenics said late on Monday that sales in the United States of its only drug, eye disease treatment Jetrea, had slowed in the second half of ...

ThromboGenics NV has announced that its partner Alcon has launched JETREA® in Germany, the second European market where the product is now available. Since May 1st, 2013, JETREA® is listed in the ...

ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the UK's National Institute for ...

Please provide your email address to receive an email when new articles are posted on . ThromboGenics has started to evaluate Jetrea as a potential treatment for retinal vein occlusion, according to a ...